RXi Pharmaceuticals (RXII) versus Oncobiologics (ONS) Financial Analysis

RXi Pharmaceuticals (NASDAQ: RXII) and Oncobiologics (NASDAQ:ONS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares RXi Pharmaceuticals and Oncobiologics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RXi Pharmaceuticals N/A -157.22% -102.29%
Oncobiologics -1,017.57% N/A -226.21%

Analyst Ratings

This is a summary of current recommendations for RXi Pharmaceuticals and Oncobiologics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RXi Pharmaceuticals 0 0 0 0 N/A
Oncobiologics 0 1 1 0 2.50

Oncobiologics has a consensus target price of $9.00, indicating a potential upside of 682.61%. Given Oncobiologics’ higher possible upside, analysts plainly believe Oncobiologics is more favorable than RXi Pharmaceuticals.

Valuation & Earnings

This table compares RXi Pharmaceuticals and Oncobiologics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RXi Pharmaceuticals $20,000.00 523.77 -$8.99 million ($10.90) -0.41
Oncobiologics $3.81 million 7.71 -$38.84 million N/A N/A

RXi Pharmaceuticals has higher earnings, but lower revenue than Oncobiologics.

Volatility and Risk

RXi Pharmaceuticals has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Oncobiologics has a beta of -0.46, indicating that its stock price is 146% less volatile than the S&P 500.

Institutional & Insider Ownership

11.7% of RXi Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.9% of Oncobiologics shares are owned by institutional investors. 5.7% of RXi Pharmaceuticals shares are owned by company insiders. Comparatively, 33.5% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Oncobiologics beats RXi Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

RXi Pharmaceuticals Company Profile

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response.

Oncobiologics Company Profile

Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company’s other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab (Erbitux).

Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.